All News
Cancer Risk From RA, Not the Drugs
While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.
Read Article
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan.
Read Article
Chronic Pain Management tools
1 Medication
2 Physical Therapy
3 Cognitive-Behavioral Therapy
4 Mindfulness Meditation
5 Acupuncture
6 Massage
7 Heat/Cold
8 TENS
9 Yoga/Tai Chi
10 Support groups https://t.co/VBvYR8VK16 https://t.co/tbfPnL1VEH
Links:
Dr. John Cush RheumNow ( View Tweet)
Using Optum claims data from 2009 to 2021, they identified 524 IgG4-RD pts (mean age 56 yrs), incidence increased over time 0.78 to 1.39/100K Pt Yrs 2015 and 2019. Prevalence (1/19) was 5.3/100K Pt-Yrs, w/ mortality rate 3.42/100 Pt-Yrs (HR 2.51) https://t.co/22eIjtC7kp https://t.co/8RlEtZiX9j
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd
Links:
Dr. John Cush RheumNow ( View Tweet)
NY Times article on a Moral Crisis for Americas doctors - the corporatization of Medicine leverages finances/incomes against physican values and practice preferences. Rheum Dr. Diana Girnita presents the Direct Medical Care option for MD autonomy https://t.co/TySD8l6I94 https://t.co/ZNTx7VVRfg
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Notes from Milan
https://t.co/cdmkiJmQrz https://t.co/w6UV85bFQ1
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: A Real Boost for Shingrix with JAKi
Dr. David Liew discusses OP0225 presented at EULAR 2023 in Milan, Italy.
https://t.co/Xgt85l6WgQ https://t.co/jPcA2GSFdm
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Concerned with MedPAC’s Cutting Part B Reimbursement
ACR took issue with the orgs reco to Congress to keep a 6% add-on payment for the lowest-cost drugs, reduce the add-on payment for mid-to-high-level drugs, and add a payment cap for the $$$ drugs.
https://t.co/IwZO88QThb https://t.co/GHjDwbHCCo
Links:
Dr. John Cush RheumNow ( View Tweet)
FAAH and FAAH-OUT - genes involved in pain perception; could these be the target of future therapies? Interesting article in FORBES bout role of FAAH and FAAH-OUT in pain. https://t.co/8FNvkVZy5R https://t.co/8Ldywt2wvq
Links:
Dr. John Cush RheumNow ( View Tweet)
Higher Genetic Loads Linked to Worse Systemic Lupus
A study of a large SLE cohort shows by genomic analysis, that higher wGRS is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations.
https://t.co/L8ZZEgcfNM https://t.co/elwDtDuSjP
Links:
Dr. John Cush RheumNow ( View Tweet)
WATCH: Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases
Dr. Peter Nash reporting from EULAR 2023 in Milan, Italy.
https://t.co/EpsPtwtJJt https://t.co/QxH8Pff6RS
Links:
Dr. John Cush RheumNow ( View Tweet)
275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR Offers Tips on Psoriasis Progression to PsA
Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR.
https://t.co/eFsWJBmzCR https://t.co/slq58tWJG6
Links:
Dr. John Cush RheumNow ( View Tweet)
Biosimilars Match Biologic Originators in RA
A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA.
https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l
Links:
Dr. John Cush RheumNow ( View Tweet)
BIOSIMILARS (93 in EU, 40 in US) are approaching a tipping point with 8 new adalimumab biosimilars in 2023. Humira sales are down ~26% in 2023. Biosimilar sales expected - $129 billion in next 5 yrs, with estimated savings of $181 billion https://t.co/HMOYaSaIBQ https://t.co/6jOujr4JXQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
https://t.co/AP89MAIlJM https://t.co/YpfWFCLF1z
Links:
Dr. John Cush RheumNow ( View Tweet)
Should we be reassured of JAK safety with new data?
Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy.
https://t.co/gxLJGHXwlm https://t.co/SgdGRJXBIi
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/DGczkgHtpZ https://t.co/TquFCuh4QG
Links:
Dr. John Cush RheumNow ( View Tweet)